Company intelligence / Profile preview

Treadwell Therapeutics

New York City, New York, United Statestreadwelltx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Treadwell Therapeutics has demonstrated promising early efficacy signals in relapsed/refractory AML with its lead PLK4 inhibitor CFI‑400945 and has advanced CFI‑402257 into Phase I/II trials for ER+/Her2– breast cancer. The company’s pipeline also includes a HPK1 inhibitor and preclinical biologic/TCR-based cell therapy programs. Clinical data to date show tolerable safety profiles and confirmed responses in targeted indications.

Therapeutic areas: Oncology
Modalities: Small moleculesBiologicsT-cell receptor (TCR)-based cell therapies
Industry: Biotech

Drug pipeline

4 assets

luvixasertib

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed; seeking partners for further development of certain assets.

Beyond the preview

Go deeper on Treadwell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Treadwell Therapeutics.

Explore the full profile